Skip to main content
USENIX
  • Conferences
  • Students
Sign in
  • Home
  • Attend
    • Registration Information
    • Registration Discounts
    • Venue, Hotel, and Travel
    • Students and Grants
    • Co-located Events
      • HotCloud '15
      • HotStorage '15
  • Program
    • At a Glance
    • Technical Sessions
  • Activities
    • Birds-of-a-Feather Sessions
    • Poster Session
  • Participate
    • Call for Papers
    • Call for Practitioner Talks
    • Instructions for Participants
  • Sponsorship
  • About
    • Conference Organizers
    • Questions
    • Services
    • Help Promote
    • Past Conferences
  • Home
  • Attend
  • Program
  • Activities
  • Participate
  • Sponsorship
  • About

sponsors

Gold Sponsor
Gold Sponsor
Gold Sponsor
Gold Sponsor
Silver Sponsor
Bronze Sponsor
Bronze Sponsor
Bronze Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Media Sponsor
Industry Partner
Industry Partner

help promote

USENIX ATC '15 button

Get more
Help Promote graphics!

connect with us


  •  Twitter
  •  Facebook
  •  LinkedIn
  •  Google+
  •  YouTube

twitter

Tweets by @usenix

usenix conference policies

  • Event Code of Conduct
  • Conference Network Policy
  • Statement on Environmental Responsibility Policy

You are here

Home » Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing
Tweet

connect with us

Privacy in Pharmacogenetics: An End-to-End Case Study of Personalized Warfarin Dosing

Authors: 

Matthew Fredrikson, Eric Lantz, and Somesh Jha, University of Wisconsin—Madison; Simon Lin, Marshfield Clinic Research Foundation; David Page and Thomas Ristenpart, University of Wisconsin—Madison
Best Paper at USENIX Security '14: Link to Paper

Abstract: 

We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient’s genotype and background. Performing an in-depth case study on privacy in personalized warfarin dosing, we show that suggested models carry privacy risks, in particular because attackers can perform what we call model inversion: an attacker, given the model and some demographic information about a patient, can predict the patient’s genetic markers.

As differential privacy (DP) is an oft-proposed solution for medical settings such as this, we evaluate its effectiveness for building private versions of pharmacogenetic models. We show that DP mechanisms prevent our model inversion attacks when the privacy budget is carefully selected. We go on to analyze the impact on utility by performing simulated clinical trials with DP dosing models. We find that for privacy budgets effective at preventing attacks, patients would be exposed to increased risk of stroke, bleeding events, and mortality. We conclude that current DP mechanisms do not simultaneously improve genomic privacy while retaining desirable clinical efficacy, highlighting the need for new mechanisms that should be evaluated in situ using the general methodology introduced by our work.

Links

Paper: 
Paper (HTML): 
Slides: 
  • Log in or    Register to post comments

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Media Sponsors & Industry Partners

Open Access Publishing Partner

© USENIX

  • Privacy Policy
  • Contact Us